• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Churchill Capital Corp XI

    7/2/26 1:16:37 PM ET
    $CCXI
    Get the next $CCXI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Churchill Capital Corp XI

    (Name of Issuer)


    Class A Ordinary Shares, $0.0001 par value

    (Title of Class of Securities)




    G2131A124

    (CUSIP Number)
    06/26/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    G2131A124


    1Names of Reporting Persons

    BlueCrest Capital Management Ltd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    JERSEY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,354,233.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,354,233.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,354,233.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.6 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    G2131A124


    1Names of Reporting Persons

    Platt Michael Edward
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,354,233.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,354,233.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,354,233.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Churchill Capital Corp XI
    (b)Address of issuer's principal executive offices:

    640 FIFTH AVENUE 12TH FLOOR, NEW YORK, NEW YORK, 10019.
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: i. BlueCrest Capital Management Limited (the "Investment Manager"), which serves as investment manager to BSMA Limited, a Cayman Islands exempted company (the "Fund"); and ii. Michael Platt ("Mr. Platt"), who serves as principal, director, and control person of the Investment Manager; with respect to the shares (as defined herein) held for the account of the Fund.
    (b)Address or principal business office or, if none, residence:

    The address of the business office of the Investment Manager and Mr. Platt is: Ground Floor Harbour Reach, La Rue de Carteret St Helier Jersey Channel Islands JE2 4HR
    (c)Citizenship:

    The Investment Manager is a company organized under the laws of Jersey, Channel Islands, operating solely out of Jersey, Channel Islands. Mr. Platt is a citizen of the United Kingdom.
    (d)Title of class of securities:

    Class A Ordinary Shares, $0.0001 par value
    (e)CUSIP Number(s):

    G2131A124
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The Investment Manager and Mr. Platt beneficially own 2,354,233 shares.
    (b)Percent of class:

    Investment Manager: 5.6% Mr. Platt: 5.6%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Investment Manager: 2,354,233.00 Mr. Platt: 2,354,233.00

     (ii) Shared power to vote or to direct the vote:

    Each of the Reporting Persons has shared power to vote or direct the vote of 0 shares of Common Stock.

     (iii) Sole power to dispose or to direct the disposition of:

    Investment Manager: 2,354,233.00 Mr. Platt: 2,354,233.00

     (iv) Shared power to dispose or to direct the disposition of:

    Each of the Reporting Persons has shared power to vote or direct the vote of 0 shares of Common Stock.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See disclosure in Items 2 and 4 hereof. The Fund is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the ordinary shares covered by the Statement that may be deemed to be beneficially owned by the Reporting Persons.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See disclosure in Item 2 hereof.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    BlueCrest Capital Management Ltd
     
    Signature:/s/ Michael Bell
    Name/Title:Authorized Signatory
    Date:07/03/2026
     
    Platt Michael Edward
     
    Signature:/s/ Steven Pariente
    Name/Title:As attorney-in-fact for Michael Platt
    Date:07/03/2026
    Get the next $CCXI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CCXI

    DatePrice TargetRatingAnalyst
    8/4/2022$81.00Buy
    Canaccord Genuity
    11/10/2021$107.00 → $110.00Strong Buy
    Raymond James
    10/11/2021$14.00 → $38.00Underweight → Neutral
    JP Morgan
    10/11/2021$64.00Mkt Perform → Outperform
    SVB Leerink
    10/11/2021$62.00 → $107.00Outperform → Strong Buy
    Raymond James
    10/8/2021$62.00 → $107.00Outperform → Strong Buy
    Raymond James
    10/8/2021Neutral → Overweight
    Piper Sandler
    7/7/2021$26.00 → $31.00Hold → Buy
    Stifel
    More analyst ratings

    $CCXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Agility Robotics Strengthens Executive Leadership Team with Appointment of Michael Beer as Chief Financial Officer

    Experienced public company finance executive joins Agility as company expands commercial momentum and prepares to become the first publicly listed U.S. pure-play humanoid robotics company.SALEM, Ore., July 23, 2026 /PRNewswire/ -- Agility Robotics, a leading humanoid robotics and Physical AI company, today announced the appointment of Michael Beer as Chief Financial Officer as the company continues to strengthen its executive leadership team ahead of its planned public listing through its previously announced business combination with Churchill Capital Corp XI (NASDAQ:CCXI). As part of this planned evolution of the leadership t

    7/23/26 8:00:00 AM ET
    $CCXI
    $NRGV
    Industrial Machinery/Components
    Miscellaneous

    Agility Opens New Fremont Facility to Accelerate Physical AI Development

    Bay Area facility will advance the AI technologies that enable its humanoid robot, Digit, to learn new skills, supporting expanded capabilities across commercial deployments.FREMONT, Calif., July 16, 2026 /PRNewswire/ -- Agility, a leading humanoid robotics and Physical AI company, today announced the opening of its new Fremont, California, facility designed to accelerate Physical AI developments that directly improve performance in customer operations. The new site will serve as the company's software and capabilities hub, where engineering teams will train, test and advance the AI technologies that enable Agility's humanoid, Digit, to learn new skills and perform more sophisticated tasks i

    7/16/26 3:00:00 PM ET
    $CCXI

    Agility Robotics and Churchill Capital Corp XI Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination

    Transaction Expected to Create The Only Publicly Listed Pure-Play Humanoid Company with Proven, Active Commercial Deployments Agility Robotics, Inc. ("Agility" or the "Company") creator of the general-purpose humanoid robot Digit, and Churchill Capital Corp XI (NASDAQ:CCXI) ("CCXI" or "Churchill XI"), a special purpose acquisition company, today announced the confidential submission of a draft registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC"). The submission of the Registration Statement marks an important milestone toward the completion of the previously disclosed proposed business combination between Agility and

    7/14/26 11:30:00 AM ET
    $CCXI

    $CCXI
    SEC Filings

    View All

    SEC Form 425 filed by Churchill Capital Corp XI

    425 - Churchill Capital Corp XI (0002074973) (Subject)

    7/16/26 5:12:22 PM ET
    $CCXI

    SEC Form 425 filed by Churchill Capital Corp XI

    425 - Churchill Capital Corp XI (0002074973) (Subject)

    7/14/26 4:34:29 PM ET
    $CCXI

    SEC Form 8-K filed by Churchill Capital Corp XI

    8-K - Churchill Capital Corp XI (0002074973) (Filer)

    7/14/26 4:30:42 PM ET
    $CCXI

    $CCXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Klein Michael Stuart bought $5,000,000 worth of Class A Ordinary Shares (500,000 units at $10.00) (SEC Form 4)

    4 - Churchill Capital Corp XI (0002074973) (Issuer)

    12/19/25 5:16:36 PM ET
    $CCXI

    $CCXI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TAVNEOS issued to CHEMOCENTRYX, INC.

    Submission status for CHEMOCENTRYX, INC.'s drug TAVNEOS (ORIG-1) with active ingredient AVACOPAN has changed to 'Approval' on 10/07/2021. Application Category: NDA, Application Number: 214487, Application Classification: Type 1 - New Molecular Entity

    10/15/21 3:42:50 PM ET
    $CCXI

    $CCXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Lapping Paul

    3 - Churchill Capital Corp XI (0002074973) (Issuer)

    3/19/26 8:44:45 PM ET
    $CCXI

    SEC Form 3 filed by new insider Murphy Stephen Anthony

    3 - Churchill Capital Corp XI (0002074973) (Issuer)

    3/19/26 8:43:25 PM ET
    $CCXI

    Officer Klein Michael Stuart bought $5,000,000 worth of Class A Ordinary Shares (500,000 units at $10.00) (SEC Form 4)

    4 - Churchill Capital Corp XI (0002074973) (Issuer)

    12/19/25 5:16:36 PM ET
    $CCXI

    $CCXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity resumed coverage on ChemoCentryx with a new price target

    Canaccord Genuity resumed coverage of ChemoCentryx with a rating of Buy and set a new price target of $81.00

    8/4/22 8:51:51 AM ET
    $CCXI

    Raymond James reiterated coverage on ChemoCentryx with a new price target

    Raymond James reiterated coverage of ChemoCentryx with a rating of Strong Buy and set a new price target of $110.00 from $107.00 previously

    11/10/21 9:06:49 AM ET
    $CCXI

    ChemoCentryx upgraded by JP Morgan with a new price target

    JP Morgan upgraded ChemoCentryx from Underweight to Neutral and set a new price target of $38.00 from $14.00 previously

    10/11/21 8:32:48 AM ET
    $CCXI

    $CCXI
    Leadership Updates

    Live Leadership Updates

    View All

    ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director

    SAN CARLOS, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022. With this appointment, the Board increases the number of directors constituting the whole Board from eight to nine. "With more than 25 years developing and refining her therapeutics commercial expertise, Jennifer is uniquely positioned to add immediate value to our TAVNEOS® (avacopan) commercial efforts," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "Jennifer's values closely align with our organization, and we are confident this addition

    7/5/22 8:30:00 AM ET
    $CCXI

    ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer

    Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product SAN CARLOS, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced the appointment of Rita I. Jain, M.D., as Executive Vice President, Chief Medical Officer. In this role, she will oversee development activities including clinical development, development operations, regulatory affairs, and drug safety and pharmacovigilance. Dr. Jain will continue to serve on the ChemoCentryx board of directors (where she has served since March of 2019) as an executive employee director. Dr. Jain, a board-certified rheumatologist, brings more than 20 years of drug de

    10/11/21 8:30:00 AM ET
    $CCXI

    ChemoCentryx Announces Appointment of Susan M. Kanaya to Board of Directors

    MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Company’s Executive Vice President and Chief Financial and Administrative Officer, to the ChemoCentryx Board of Directors effective March 2, 2021. “Susan Kanaya’s many fundamental contributions have been key to ChemoCentryx’s growth and prosperity,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “Over many formative years of our enterprise, she ensured our strong financial position, allowing us to achieve our operational plans and thus increasing shareholder value while serving patients’ needs. As a

    3/8/21 8:30:00 AM ET
    $CCXI

    $CCXI
    Financials

    Live finance-specific insights

    View All

    AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX

    TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., Oct. 20, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ:CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $52 per share in cash, representing aggregate merger consideration of approximately $3.7 billion. "ChemoCentryx enhances Amgen's leading inflammation and nephrology portfolio and includes TAVNEOS® (avacopan), a first-in-cl

    10/20/22 9:05:00 AM ET
    $AMGN
    $CCXI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call

    SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET. The call is being cancelled due to the August 4, 2022, announcement that Amgen and ChemoCentryx, Inc. signed a definitive agreement pursuant to which Amgen would acquire ChemoCentryx. ChemoCentryx filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, on August 8, 2022. About ChemoCentryx ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. 

    8/9/22 8:30:00 AM ET
    $CCXI

    ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022

    SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that the Company's second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 9, 2022 to discuss these results and to answer questions. To participate by telephone, please dial (800) 715-9871 (Domestic) or (646) 307-1963 (International). The conference ID number is 9726781. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast wil

    8/2/22 4:05:00 PM ET
    $CCXI

    $CCXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by ChemoCentryx Inc. (Amendment)

    SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)

    9/12/22 11:13:14 AM ET
    $CCXI

    SEC Form SC 13G/A filed by ChemoCentryx Inc. (Amendment)

    SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)

    2/9/22 3:33:37 PM ET
    $CCXI

    SEC Form SC 13G/A filed by ChemoCentryx Inc. (Amendment)

    SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)

    2/9/22 9:11:44 AM ET
    $CCXI